Bronchopulmonary Dysplasia (BPD)

AyuVis is developing a new class of drug to treat bronchopulmonary dysplasia (BPD) with promising preclinical data. BPD is an orphan disease that affects 1.8M children worldwide annually and is growing and is considered one of the largest causes of neonatal death in US.

The incidence of BPD ranges between 15-50% in very low birth weight infants (VLBWI). VLBWI with BPD develop pulmonary hypertension (PH) in 17-45%, which worsens the prognosis and increases the mortality rate. There is no effective drug on the market to treat this condition. There is a continuing unmet need to develop non-steroidal therapies that will treat hyper-inflammation in lungs, prevent tissue and organ damage, restore function, and decrease mortality without compromising neonatal immunity. 

The unmet need for a solution

Bronchopulmonary dysplasia (BPD) is one of the most important sequels of preterm birth and one of the most serious chronic lung diseases in infancy. The etiology of BPD is multi-factorial and the prevalence is inversely related to birth weight and gestational age.


Expected Benefits of AyuVis Compounds:

  • Increased patient survival rates

  • Reduced use of supplemental oxygen after discharge

  • Reduced lifetime respiratory problems 

  • Reduced hospital costs

AyuVis is developing a novel small immune-modulating agent that enhances the body’s ability to fight inflammation and restore lung function when administered intravenously. This could help reduce or prevent BPD in premature babies, and reduce their hospital stay.

The anti-inflammatory properties differ from current steroids in that they do not suppress normal immune function but appear to have a synergistic effect.   

Overall market potential of an AyuVis BPD drug is driven by:

  • BPD is growing due to the increased survival of pre-term babies with underdeveloped lungs

  • BPD treatment accounts for > $6B in cumulative costs to the US health care system

  • BPD affects approximately 30,000 babies in the US and EU each year

  • There are no FDA approved therapies for BPD

  • AyuVis estimates the US market to be over $800 million with a global market potential of $2 billion